% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rojospan rojospan Nov 10, 2012 9:52 PM Flag

    GS-7977 + RBV trial (ELECTRON) is a huge failure


    GT 1 treatment naive SVR 12 --------84%
    My understanding is that GT 1a is harder to treat then GT 1 b which is harder to treat then GT2/3.
    Things are not making sense here to me if SVR 12 is only 60% for GT 2/3.

    AF and ISI guy are supporters of GILD?
    I am still waiting to see safety data on GS5885 and GS 7977 combo.

    VRTX has made a very good decision in combining GSK 508 and TMC 435 with VX 135 in my opinion. If VRTX keeps close to 1 B/ yr in Hep C revenues, we will do well. I am eager to see SVR 24 intrim data for VX 222, VX 950 and Ribavirin in GT 1 a patient. 60 patient trial entrollement finished faster than expected and 1/2 of them should have some sort of read out in next few weeks.

    BCRX flu drug Peramivir failed phase III in influenza and is a positive news for VX 787
    Xeljanz approval for 5 mg Bid dose is again a good news for VX 509.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
90.38+1.19(+1.33%)May 27 4:00 PMEDT